OBR Daily Commentary

forumImage

Veru's Experimental Drug Reduces Hot Flashes In Men In Mid-Stage Study

(Reuters) Jan 13, 2020 - Veru Inc said on Monday a higher dose of its experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: January 13, 2020)

quotesHot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to treat them are important for quality of survivorship. It is not surprising that an estrogenic drug would be effective. It will be important to learn more about any side effects that might emerge with additional studies.quotes

Add Comment 1 Comment
forumImage

Myovant to Submit Lead Drug For Prostate Cancer Approval After Phase 3 Results

(BioPharma Dive) Nov 19, 2019 - Myovant Sciences said Tuesday a late-stage trial studying its lead drug in advanced prostate cancer met its primary and secondary goals, clearing the path for the company to next year submit the experimental therapy for Food and Drug Administration approval. The Phase 3 study tested relugolix, a so-called GnRH receptor antagonist, against leuprolide acetate injection, which is a standard androgen deprivation therapy. Two-thirds of 934 enrolled patients received Myovant's treatment while one-third received leuoprolide acetate.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: November 19, 2019)

quotesAn oral option for primary hormonal therapy will be attractive for some patients, particularly those that are interested in intermittent therapy, more rapid testosterone recovery after stopping therapy, and rapid onset of action. Pricing, co-pays, and other practical considerations as well patient and physician preferences and habits will be important in defining the role of this new drug, if approved.quotes

Add Comment 1 Comment
forumImage

The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

(Yahoo! Finance) Nov 11, 2019 - Prostate cancer remains the most frequently diagnosed cancer within the Veterans Affairs with 15,000 Veterans newly diagnosed annually.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: November 11, 2019)

quotesThe VA serves substantial numbers of veterans living with prostate cancer, and offers unique opportunities for research advances through its large scale initiatives and integrated health care delivery model. The PCF's investment will complement the VAs commitment and make substantial contributions to veterans and to prostate cancer research.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...